• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
In conclusion, patients in BP strata ≥ 150/90 mmHg, but not patients in BP strata < 130/70 mmHg, were at increased risk for adverse outcomes in this hypertensive, high-risk population. Although benefit in preventing MI in relation to preventing stroke levels off for the lowest BPs, these data provide no support for a J-curve in the treatment of high-risk hypertensive patients . The increase in the ratio of MI to stroke with lower DBP indicates target organ heterogeneity in that the optimal on-treatment DBP for cerebroprotection is below that for cardioprotection. PMID: 26511535 [PubMed - in process]
Source: Blood Pressure - February 14, 2016 Category: Hematology Tags: Blood Press Source Type: research

Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial
This study was designed to examine whether valsartan or fluvastatin can reduce the risk of non-permanent AF in patients with hypertension.Methods/designThe VF-HT-AF study is a multicenter, randomized, open-label, four-arm parallel group study with comparative evaluation of valsartan and fluvastatin as upstream therapies for the treatment of non-permanent AF complicated by hypertension. The primary outcome measure is change in the development of paroxysmal AF into persistent or permanent AF, the development of persistent AF to permanent AF, and change in incidence of overall and persistent AF recurrence, as evaluated by 7-d...
Source: Trials - August 7, 2015 Category: Journals (General) Authors: Wen-Wei QiTong LiuGang XuLi-Feng LiYing-Zi LiangLan YeGuang-Ping Li Source Type: research

Predictors of Stroke in Patients With Impaired Glucose Tolerance: Results From the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Trial Brief Reports
Conclusions— The most powerful predictors of stroke in patients with impaired glucose tolerance included a combination of established risk factors and novel variables, such as previous venous thromboembolism and elevated waist circumference, allowing moderately effective identification of high-risk individuals.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Preiss, D., Giles, T. D., Thomas, L. E., Sun, J.-L., Haffner, S. M., Holman, R. R., Standl, E., Mazzone, T., Rutten, G. E., Tognoni, G., Chiang, F.-T., McMurray, J. J. V., Califf, R. M. Tags: Cerebrovascular disease/stroke, Risk Factors, Glucose intolerance Brief Reports Source Type: research